JP Morgan Downgrades Upstream Bio to Neutral, Lowers Price Target to $8
Benzinga Newsdesk 4 months ago
NewsDowngradesPrice TargetAnalyst Ratings
JP Morgan analyst Tessa Romero downgrades Upstream Bio (NASDAQ:UPB) from Overweight to Neutral and lowers the price target from $35 to $8.
JP Morgan analyst Tessa Romero downgrades Upstream Bio (NASDAQ:UPB) from Overweight to Neutral and lowers the price target from $35 to $8.